J Eur Acad Dermatol Venereol 2023 doi 10.1111/jdv.19682 Epub ahead of print
This monocentric, retrospective clinical study by Mastorino, et al. found that ixekizumab demonstrated efficacy an safety in patients with PsA and PsO for up to five years. Being a super-responder was significantly associated with a lower rate of discontinuation, while high BMI was associated with a lower achievement of more than one PSAI measure up to Week 104.
This study observed patients for up to five years at the Dermatologic Clinic of the University of Turin, Italy. Cox analysis evaluated possible predictive factors of discontinuation. Mean PASI and PASI100, 90, and ≤3 were used as outcomes of effectiveness on observed patients. Logistic regression identified possible predictive factors of response.